BCL2 and Thrombocytopenia: The development of the pan-Bcl-2 inhibitor obatoclax has been ceased due to low response rates and neurologic and psychiatric side effects [1,2,32], and the use of navitoclax, which not only inhibits Bcl-2 but also Bcl-xL and Bcl-w, is limited due to acute, dose-dependent thrombocytopenia [1,2,32].